Mehdi Najar1, Robim M Rodrigues2, Karolien Buyl2, Steven Branson2, Tamara Vanhaecke2, Laurence Lagneaux1, Vera Rogiers2, Joery De Kock3. 1. Laboratory of Clinical Cell Therapy, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 2. Department of In Vitro Toxicology and Dermato-Cosmetology, Center for Pharmaceutical Research, Vrije Universiteit Brussel, Brussels, Belgium. 3. Department of In Vitro Toxicology and Dermato-Cosmetology, Center for Pharmaceutical Research, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: jdekock@vub.ac.be.
Abstract
BACKGROUND AIMS: Adult human subcutaneous adipose tissue harbors a multipotent stem cell population, the so-called human adipose tissue-derived mesenchymal stromal cells (AT-MSCs). These cells are able to differentiate in vitro into various cell types and possess immunomodulatory features. Yet procedures to obtain AT-MSCs can vary significantly. The two most extensively used AT-MSC purification techniques are (i) density gradient centrifugation using Ficoll and (ii) red blood cell (RBC) lysis buffer treatment of the stromal vascular fraction. In the context of potential clinical cell therapy, the stem cell yield after purification and upon consecutive passages, as well as the purity of the obtained cell population, are of utmost importance. METHODS: We investigated the expansion capacity and purity of AT-MSCs purified by both procedures immediately after isolation and upon consecutive passages. We also investigated possible purification-dependent differences in their expression of immune-inhibitory factors and cell adhesion molecules. RESULTS: We found that RBC lysis buffer treatment is a more robust and easier method to purify AT-MSCs than density gradient fractionation. However, the resulting AT-MSC-RBC population contains a significantly higher number of CD34(+) cells, particularly during the first passages after plating. From passage 4 onward, no significant differences could be observed between both populations with respect to the immunophenotype, expansion capacity and expression of immune inhibitory factors and cell adhesion molecules. CONCLUSIONS: Our data show that RBC lysis buffer treatment may be a good alternative to density fractionation, providing a faster, more robust and easier method to purify AT-MSCs with biologically preserved characteristics.
BACKGROUND AIMS: Adult human subcutaneous adipose tissue harbors a multipotent stem cell population, the so-called human adipose tissue-derived mesenchymal stromal cells (AT-MSCs). These cells are able to differentiate in vitro into various cell types and possess immunomodulatory features. Yet procedures to obtain AT-MSCs can vary significantly. The two most extensively used AT-MSC purification techniques are (i) density gradient centrifugation using Ficoll and (ii) red blood cell (RBC) lysis buffer treatment of the stromal vascular fraction. In the context of potential clinical cell therapy, the stem cell yield after purification and upon consecutive passages, as well as the purity of the obtained cell population, are of utmost importance. METHODS: We investigated the expansion capacity and purity of AT-MSCs purified by both procedures immediately after isolation and upon consecutive passages. We also investigated possible purification-dependent differences in their expression of immune-inhibitory factors and cell adhesion molecules. RESULTS: We found that RBC lysis buffer treatment is a more robust and easier method to purify AT-MSCs than density gradient fractionation. However, the resulting AT-MSC-RBC population contains a significantly higher number of CD34(+) cells, particularly during the first passages after plating. From passage 4 onward, no significant differences could be observed between both populations with respect to the immunophenotype, expansion capacity and expression of immune inhibitory factors and cell adhesion molecules. CONCLUSIONS: Our data show that RBC lysis buffer treatment may be a good alternative to density fractionation, providing a faster, more robust and easier method to purify AT-MSCs with biologically preserved characteristics.
Authors: Irena Walecka; Paulina Gil-Kulik; Arkadiusz Krzyżanowski; Marcin Czop; Dariusz Galkowski; Jolanta Karwat; Piotr Chomik; Małgorzata Świstowska; Anna Kwaśniewska; Anna Bogucka-Kocka; Janusz Kocki Journal: Med Sci Monit Date: 2017-04-19
Authors: Laura C Rose; Deepak K Kadayakkara; Guan Wang; Amnon Bar-Shir; Brooke M Helfer; Charles F O'Hanlon; Dara L Kraitchman; Ricardo L Rodriguez; Jeff W M Bulte Journal: Stem Cells Transl Med Date: 2015-10-28 Impact factor: 6.940
Authors: Sam L Francis; Serena Duchi; Carmine Onofrillo; Claudia Di Bella; Peter F M Choong Journal: Stem Cells Int Date: 2018-04-03 Impact factor: 5.443